Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from the Benelux countries Belgium, Luxembourg and The Netherlands or involving organisations from these countries.

Total search results: 1906 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Neurent Medical–Life Sciences Partners: investment, 202101 financing round Series B totalling €21m incl lead investor LSP Health Economics Fund 2 2021-01-20
Neurent Medical–SEVERAL: investment, 202101 financing round Series B €21m led by LSP Health Economics Fund 2 2021-01-20
CoviCept Therapeutics–Forbion: investment, 202101 seed investment $2.3 from Forbion 2021-01-19
Novasep–Thermo Fisher: investment, 202101 acquisition €725m in cash of viral vector manufacturing business Henogen SA in Belgium by Thermo Fisher 2021-01-15
NewAmsterdam Pharma–SEVERAL: investment, 202101 financing round Series A €160m co-led by Morningside Ventures + Ascendant BioCapital 2021-01-14
Affimed–SVB: credit, 202101–202511 up to €25m loans in three tranches with €10m at closing plus €15m milestone-based 2021-01-11
Novartis–BeiGene: tisleizumab, 202101– license $650m upfront + royalties + milestones developm + commercialisation in US, CA, MX + Europe + RU + JP 2021-01-11
BioGeneration Ventures–BMS: investment, 202101 final closing of BGV IV totalling €140m incl investor BMS 2021-01-07
BioGeneration Ventures–EU (govt): investment, 202101 final closing of BGV IV totalling €140m incl investor European Investment Fund 2021-01-07
BioGeneration Ventures–Germany (govt): investment, 202101 final closing of BGV IV totalling €140m incl investor KfW Capital 2021-01-07
BioGeneration Ventures–Industriens Pension: investment, 202101 final closing of BGV IV totalling €140m incl investor Industriens Pension 2021-01-07
BioGeneration Ventures–Instinctif Partners: public relations, 202101 service existent by Instinctif 2021-01-07
BioGeneration Ventures–Lilly: investment, 202101 final closing of BGV IV totalling €140m incl investor Eli Lilly 2021-01-07
BioGeneration Ventures–Novo Group: investment, 202101 final closing of BGV IV totalling €140m incl investor Novo Ventures 2021-01-07
BioGeneration Ventures–Schroders: investment, 202101 final closing of BGV IV totalling €140m incl investor Schroder Adveq 2021-01-07
BioGeneration Ventures–SEVERAL: investment, 202101 final closing of BGV IV with €140m incl Lilly + Novo Ventures + BMS + Schroder Adveq et al 2021-01-07
Volta Medical–Gilde Investment: investment, 202101 financing round totalling $28m incl lead investor Gilde Healthcare 2021-01-05
Volta Medical–SEVERAL: investment, 202101 financing round $28m led by Gilde Healthcare 2021-01-05
Qiagen–Wellcome Trust: COSMIC Database, 202101– distribution excl rights to license + distribute COSMIC for commercial use 2021-01-01
Immunicum–Van Herk: investment, 202012c largest shareholder holding 43% after merger of Immunicum with DCprime 2020-12-31
Univercells–Farallon Capital: investment, 202012 financing round Series C 2nd closing totalling €20m incl new investor Farallon Capital Management 2020-12-17
Univercells–Korea Investment Partners: investment, 202012 financing round Series C 2nd closing totalling €20m incl new investor KIP Bio Global Fund 2020-12-17
Univercells–SEVERAL: investment, 202012 financing round Series C 2nd closing €20m with Soros EDF + Farallon Capital et al 2020-12-17
Univercells–Soros Economic Development Fund: investment, 202012 financing round Series C 2nd closing totalling €20m incl new investor Soros EDF 2020-12-17
Univercells–TheClubDeal Fund: investment, 202012 financing round Series C 2nd closing totalling €20m incl new investor TheClubDeal Fund 2020-12-17
Slack Technologies–Salesforce: investment, 202012– acquisition $27.7b in cash + shares of Slack by Salesforce ANNOUNCED 2020-12-01
Innatera Nanosystems–btov Partners: investment, 202011 seed financing round totalling €5m incl co-lead investor btov Industrial Technologies Fund 2020-11-25
Innatera Nanosystems–MIG Fonds: investment, 202011 seed financing round totalling €5m incl co-lead investor MIG Verwaltungs AG 2020-11-25
Innatera Nanosystems–SEVERAL: investment, 202011 seed financing round €5m co-lead by MIG Verwaltungs AG + btov Industrial Technologies Fund 2020-11-25
Galapagos–Selvita: drug discovery services, 202011– 202512 supply for 5y by Fidelta after sale by Galapgaos to Selvita 2020-11-23
Galapagos–Selvita: investment, 202011– acquisition 100% of Fidelta d.o.o. for €31.2m in cash by Selvita SA 2020-11-23
Achilles Therapeutics–Forbion: investment, 202011 financing round Series C totalling £52.7m incl existing investor Forbion 2020-11-19
Achilles Therapeutics–SEVERAL: investment, 202011 financing round Series C £52.7m with new + existing investors 2020-11-19
SynOx Therapeutics–Forbion: investment, 202011 financing round Series A totalling €37m incl co-investor Forbion 2020-11-19
SynOx Therapeutics–Gimv: investment, 202011 financing round Series A totalling €37m incl co-investor Gimv 2020-11-19
SynOx Therapeutics–SEVERAL: investment, 202011 financing round Series A €37m co-led by HealthCap + Medicxi with Forbion + Gimv 2020-11-19
BioInvent–Van Herk: investment, 202011 existent Van Herk is largest shareholder of BioInvent 2020-11-18
DCprime–Immunicum: investment, 202011– merger with former Immunicum shareholders holding 56% + Van Herk holding 43% of combined company ANNOUNCED 2020-11-18
Pharvaris–Bain Capital: investment, 202011 financing round Series C totalling $80m incl existing + co-investor Bain Capital Life Sciences 2020-11-18
Pharvaris–Cormorant Asset Management: investment, 202011 financing round Series C totalling $80m incl new + co-investor Cormorant Asset Management 2020-11-18
Pharvaris–Foresite Capital: investment, 202011 financing round Series C totalling $80m incl existing + co-investor Foresite Capital 2020-11-18
Pharvaris–General Atlantic: investment, 202011 financing round Series C totalling $80m incl new + co-lead investor General Atlantic 2020-11-18
Pharvaris–Rockefeller: investment, 202011 financing round Series C totalling $80m incl existing + co-investor Venrock Health Capital Partners 2020-11-18
Pharvaris–SEVERAL: investment, 202011 financing round Series C $80m co-led by Viking Global Investors + General Atlantic 2020-11-18
Pharvaris–VenBio: investment, 202011 financing round Series C totalling $80m incl existing + co-investor venBio Partners 2020-11-18
Pharvaris–Viking Global Investors: investment, 202011 financing round Series C totalling $80m incl new + co-lead investor Viking Global Investors 2020-11-18
Lead Pharma–LifeSpring: public relations, 202011 service existent by LifeSpring Communications 2020-11-16
Roche–Lead Pharma: small-molecule immuno modulators, 202011– collab + license agreem up to €260m incl €10m upfront plus royalties 2020-11-16
Apaxen–LifeSpring: public relations, 202011 service existent by LifeSpring Life Sciences Communications 2020-11-12
Handl Therapeutics–UCB: investment, 202011 acquisition of Handl Therapeutics by UCB 2020-11-12
Catalym–SEVERAL: investment, 202011 financing round Series B €50m led by Vesalius Biocapital III 2020-11-10
Catalym–Vesalius Biocapital: investment, 202011 financing round Series B totalling €50m incl lead investor Vesalius Biocapital III 2020-11-10
The Protein Brewery–SEVERAL: investment, 202011 financing round Series A €22m led by Novo Holdings 2020-11-03
Eurofins–Waters: mass spectrometer, 202011 supply existent Radian ASAP System beta customer Eurofins Forenscis Teddington 2020-11-02
Fountain Healthcare Partners–Kyowa Kirin: investment, 202011 final closing of Fund III totalling addit €7m incl new investor Kyowa Kirin Co Ltd 2020-11-02
Fountain Healthcare Partners–SEVERAL: investment, 202011 final closing of Fund III addit €7m incl Kyowa Kirin bringing total fund to hard cap of €125m 2020-11-02
Kiadis–Sanofi: investment, 202011– cash tender offer €308m for Kiadis Pharma NV at €5.45 per share (272% premium over closing price on 30 Oct) 2020-11-02
Unilever–Eagle Genomics: microbiomics, <202010 collab use of e[datascientist] platform to support claims for enzyme-containing Zendium toothpaste 2020-10-27
Gilead–ProteoNic: rec protein production technology, 202010– licensel €na to use 2G UNic technology to Immunomedics 2020-10-20
ProteoNic–LifeSpring: public relations, 202010 service existent by LifeSpring Life Sciences Communications 2020-10-20
Topas Therapeutics–BioMedPartners: investment, 202010 financing round Series B totalling €22m incl new + co-lead investor BioMedPartners 2020-10-19
Topas Therapeutics–Boehringer: investment, 202010 financing round Series B totalling €22m incl existing + co-investor BIVF 2020-10-19
Topas Therapeutics–Gimv: investment, 202010 financing round Series B totalling €22m incl existing + co-investor Gimv 2020-10-19
Topas Therapeutics–SEVERAL: investment, 202010 financing round Series B €22m co-led by Vesalius + BioMedPartners plus all existing investors 2020-10-19
Topas Therapeutics–Vesalius Biocapital: investment, 202010 financing round Series B totalling €22m incl new + co-lead investor Vesalius Biocapital III 2020-10-19
Oncopeptides–EU (govt): credit, 202010– unsecured €40m loan facility in three tranches with each 5y maturity from EIB 2020-10-14
Neogene Therapeutics–Twist Bioscience: cell therapy, 202010– collab strategic partnership using DNA synthesis platform to develop T cell therapies 2020-10-13
Novartis–Merck (DE): Nanobodies, 202010– license €50m upfront + €400m milestones to M6495 anti-ADAMTS5 Nanobody for osteoarthritis 2020-10-06
Ynsect–SEVERAL: investment, 202010 financing round Series C extension to total of $372m led by Astanor Ventures 2020-10-06
Sophia Genetics–Alychlo: investment, 202010 financing round Series F totalling $110m incl existing + co-investor Alychlo 2020-10-01
Mosa Meat–Bell Food: investment, 202009 financing round Series B 1st closing totalling $55m incl existing + co-investor Bell Food Group 2020-09-25
Mosa Meat–Blue Horizon Ventures: investment, 202009 financing round Series B 1st closing totalling $55m incl new + lead investor Blue Horizon Ventures 2020-09-25
Mosa Meat–Merck (DE): investment, 202009 financing round Series B 1st closing totalling $55m incl existing + co-investor M Ventures 2020-09-25
Mosa Meat–SEVERAL: investment, 202009 financing round Series B 1st closing $55m led by Blue Horizon Ventures 2020-09-25
AM-Pharma–Bellevue: investment, 202009 existent portfolio company of BB Pureos Bioventures LP 2020-09-23
Bellevue–SEVERAL: investment, 202009 Closing $170m of BB Pureos Bioventures LP fund 2020-09-23
Salvia BioElectronics–ABP (NL): investment, 202009 financing round Series A totalling €21m incl new + co-lead investor Inkef Capital 2020-09-22
Salvia BioElectronics–Dolby Family Ventures: investment, 202009 financing round Series A totalling €21m incl co-investor Dolby Family Ventures 2020-09-22
Salvia BioElectronics–Netherlands (govt): credit, 202009 deferred risk-bearing Innovation Credit €5m from RVO 2020-09-22
Salvia BioElectronics–Netherlands (govt): investment, 202009 financing round Series A totalling €21m incl co-investor BOM Brabant Ventures 2020-09-22
Salvia BioElectronics–Panakès Partners: investment, 202009 financing round Series A totalling €21m incl new + co-lead investor Panakès Partners 2020-09-22
Salvia BioElectronics–SEVERAL: investment, 202009 financing round Series A €21m co-led by Panakès Partners + Inkef Capital + SHS 2020-09-22
Salvia BioElectronics–SHS: investment, 202009 financing round Series A totalling €21m incl new + co-lead investor SHS 2020-09-22
Salvia BioElectronics–Thuja Capital: investment, 202009 financing round Series A totalling €21m incl co-investor Thuja Capital 2020-09-22
Sundew–Novo Group: investment, 202009 seed financing round totalling €1.4m inkl DKK10m (€1.34m) from Novo Nordisk BII 2020-09-22
Sundew–SEVERAL: investment, 202009 seed financing round €1.4m with €1.34m from Novo Nordisk BII + €85k from StartLife 2020-09-22
Sundew–StartLife (NL): investment, 202009 seed financing round totalling €1.4m inkl €85k from StartLife 2020-09-22
Lava Therapeutics–Bellevue: investment, 202009 financing round Series C totalling $83m incl new + co-investor BB Pureos Bioventures 2020-09-17
Lava Therapeutics–Gilde Investment: investment, 202009 financing round Series C totalling $83m incl existing + co-investor Gilde Healthcare 2020-09-17
Lava Therapeutics–Merck (US): investment, 202009 financing round Series C totalling $83m incl existing + co-investor MRL Ventures Fund LLC 2020-09-17
Lava Therapeutics–Novo Group: investment, 202009 financing round Series C totalling $83m incl new + co-lead investor Novo Ventures 2020-09-17
Lava Therapeutics–Redmile Group: investment, 202009 financing round Series C totalling $83m incl new + co-investor Redmile Biopharma Investments 2020-09-17
Lava Therapeutics–Sanofi: investment, 202009 financing round Series C totalling $83m incl new + co-lead investor Sanofi Ventures 2020-09-17
Lava Therapeutics–SEVERAL: investment, 202009 financing round Series C $83m co-led by Novo Ventures + Sanofi Ventures 2020-09-17
Lava Therapeutics–Versant Ventures: investment, 202009 financing round Series C totalling $83m incl existing + co-investor Versant 2020-09-17
Lava Therapeutics–Ysios Capital: investment, 202009 financing round Series C totalling $83m incl new + co-investor Ysios Capital 2020-09-17
Neogene Therapeutics–EcoR1 Capital: investment, 202009 financing round Series A totalling $110m incl new + co-lead investor EcorR1 Capital 2020-09-14
Neogene Therapeutics–Jeito Capital: investment, 202009 financing round Series A totalling $110m incl new + co-lead investor Jeito Capital 2020-09-14
Neogene Therapeutics–Polaris Partners: investment, 202009 financing round Series A totalling $110m incl new + co-investor Polaris Partners 2020-09-14
Neogene Therapeutics–Pontifax: investment, 202009 financing round Series A totalling $110m incl new + co-investor Pontifax 2020-09-14
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20  next pagenext page



Advertisement

Picture ConsulTech GmbH RnD Credit Germany 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [iito] Made Without Love 650x80px

» top